Journals / Retina-Vitreus / 2010 / Cilt: 18 - Sayı: 3

Patolojik miyopiye bağlı koroidal neovaskülarizasyonda kombinasyon tedavisi

Management of choroidal neovascularization in pathologic myopia: Combined therapy

Pages
197–202
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results of this study suggest that PDT combined with IVB seems to be effective in treating myopic CNV by reducing retreatment needs and improving visual acuity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To report the outcome of combined verteporfin photodynamic therapy (PDT) and intravitreal bevacizumab (IVB) for the treatment of choroidal neovascularization (CNV) due to pathologic myopia.
📊
Key Findings & Data:Materials and Methods: The reports of the patients with CNV secondary to pathologic myopia who received PDT and 2.5 mg of IVB were reviewed.
💡
Conclusion & Impact:Conclusion: The results of this study suggest that PDT combined with IVB seems to be effective in treating myopic CNV by reducing retreatment needs and improving visual acuity.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To report the outcome of combined verteporfin photodynamic therapy (PDT) and intravitreal bevacizumab (IVB) for the treatment of choroidal neovascularization (CNV) due to pathologic myopia. Materials and Methods: The reports of the patients with CNV secondary to pathologic myopia who received PDT and 2.5 mg of IVB were reviewed. All of the eyes were examined with optic coherence tomography and fluorescein anjiography in addition to Snellen visual acuity (VA) assessment and total ophthalmologic examination both before and after treatment. An activity score (AS) was given to each lesion during all visits. Retreatments were done if the AS is at least 7 during the control visits. Results: Six patients were included. The mean logMAR VA was 1.30 before treatment, 0.86 at the last visit (p<0.05). Mean improvement in VA was 2 (range, -2 to 4) Snellen lines. The mean AS was significantly lower than the baseline at each visit (p<0.05). Initial foveal thickness improved from 394.4±222.7 &#956;m to 175.4±25.4 &#956;m after the last follow-up (p<0.05). The mean number of PDT/patient was 1.7 and that of IVB was 2.5 during the 28 months of a mean follow-up. Conclusion: The results of this study suggest that PDT combined with IVB seems to be effective in treating myopic CNV by reducing retreatment needs and improving visual acuity.

Özet

Amaç: Patolojik myopiye bağlı koroidal neovaskülarizasyonda (KNV) verteporfinli fotodinamik tedavi (FDT) ve intravitreal bevacizumab (İVB) kombinasyon tedavisinin sonuçlarının bildirilmesi. Gereç ve Yöntem: Patolojik myopiye bağlı KNV nedeniyle FDT ve 2.5 mg İVB tedavisi alan hastaların kayıtları retrospektif olarak incelendi. Gözlerin tümü tedaviden önce ve sonra Snellen görme keskinliği değerlendirmesi (GK) ve tam oftalmolojik muayeneye ek olarak optik koherens tomografi ve floresein anjiografi ile değerlendirildi. Bütün kontrol vizitlerinde her lezyona bir aktivite skoru (AS) verildi. Kontrol vizitlerinde AS’nin en az 7 olması durumunda tekrar tedavi uygulandı. Bulgular: Çalışmaya toplam 6 hasta dahil edildi. LogMAR GK tedaviden önce 1.30 iken, son kontrolde 0.86 idi (p<0.05). GK’de ortalama 2 (-2-4) Snellen sırası artış izlendi. AS her kontrolde başlangıçtaki değere gore anlamlı olarak düşük bulundu (p<0.05). Başlangıç fovea kalınlığı 394.4±222.7 μm iken son takipteki fovea kalınlığı 175.4±25.4 μm idi (p<0.05). Ortalama 28 aylık takip süresi sonunda ortalama FDT/hasta sayısı 1.7 iken İVB sayısı 2.5 idi. Tartışma: Bu çalışmanın sonuçlarına gore myopik KNV tedavisinde FDT ve İVB kombinasyon tedavisi hem tekrar tedavi ihtiyacını azaltarak hem de görme keskinliğinde artış sağlayarak, etkili bir tedavi seçeneği gibi görülmektedir.

🔖

Cite This Article

ÖZDEK, Ş., GEDİZ, B. Ş., EKİCİ, F., HASANREİSOĞLU, B. (2010). Patolojik miyopiye bağlı koroidal neovaskülarizasyonda kombinasyon tedavisi. Retina-Vitreus, Cilt: 18 - Sayı: 3, 197–202. https://ajindex.com/articles/307742

References (14)

  1. Hotchkiss ML, Fine SL.: Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91:177-183
  2. Cohen SY, Laroche A, Leguen Y, et al.: Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241-1244
  3. Ohno-Matsui K, Yoshida T, Futagami S, et al.: Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathological myopia. Br J Ophthalmol. 2003;87:570-573
  4. Secrétan M, Kuhn D, Soubrane G, et al.: Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7:307-316 5. Verteporfin in Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no
  5. Ophthalmology. 2001;108:841-852
  6. Blinder KJ, Blumenkranz MS, Bressler NM, et al.: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no
  7. Ophthalmology. 2003;110:667-673
  8. Gelisken F, Inhoffen W, Hermann A, et al.: Verteporfin photodynamic therapy for extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2004;242:926-930
  9. Lam DS, Liu DT, Fan DS, et al.: Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye. 2005;19:834-840
  10. Schnurrbusch UE, Jochmann C, Wiedemann P, et al.: Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2005;243:829-833
  11. Rosenfeld PJ, Moshfeghi AA, Puliafito CA.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335
  12. Avery RL, Pieramici DJ, Rabena MD, et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372
  13. Emerson MV, Lauer AK, Flaxel CJ, et al.: Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439-444
  14. Yamamoto I, Rogers AH, Reichel E, et al.: Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Op